Sex as a Potential Moderator for Baclofen Response in the Treatment of Alcohol Dependence

Kirsten C Morley, Eva Louie, Tristan Hurzeler, Andrew Baillie, Glenys Dore, Nghi Phung, Paul S Haber, Kirsten C Morley, Eva Louie, Tristan Hurzeler, Andrew Baillie, Glenys Dore, Nghi Phung, Paul S Haber

Abstract

Background and aims: Recent studies indicate that sex may moderate the response to baclofen in the treatment of alcohol use disorder (AUD). We conducted a secondary analysis of a double-blind randomized controlled trial, Baclofen in the treatment of Alcohol Liver Disease (BacALD), to examine the moderating role of sex on treatment response to baclofen in reducing alcohol consumption.

Methods: Alcohol-dependent patients (n = 104 including 74 men and 30 women) were treated for 12 weeks with baclofen (30 mg/day or 75 mg) or placebo. Predefined primary outcomes included time to lapse (any drinking) and relapse (≥ 5 drinks per day in men and ≥ 4drinks per day in women). Other outcomes included drinks per drinking day, the number of heavy drinking days, and percentage of days abstinent. We also examined the frequency of adverse events with an exploratory dose-response analysis.

Results: There was a main effect of baclofen for days to first lapse for women (Log Rank: χ2 = 6.23, p = 0.01, d = 0.49) but not for men (Log Rank: χ2 = 2.48, p = 0.12, d = 0.22) and a marginal effect of baclofen for days to first relapse for women (Log Rank: χ2 = 3.15, p = 0.08, d = 0.27) but not for men (Log Rank: χ2 = 2.03, p = 0.16, d = 0.17). There were no significant effects of sex on the frequency of adverse events reported for the combined-dose or between-dose analysis (all p > 0.44).

Conclusion: Baclofen significantly delayed the time to lapse for women but not male participants. These findings provide some support for the hypothesis that sex may be a potential moderator of baclofen response in the treatment of AUD.

Trial registration: https://ichgcp.net/clinical-trials-registry/NCT01711125, identifier: NCT01711125.

Keywords: alcohol dependence; alcohol use disorder; baclofen; gender; pharmacotherapy; sex; treatment.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Morley, Louie, Hurzeler, Baillie, Dore, Phung and Haber.

References

    1. WHO. Global Information System on Alcohol and Health (2015). Available online at: (accessed October 01, 2021).
    1. Morley KC, Perry CJ, Watt J, Hurzeler T, Leggio L, Lawrence AJ, et al. . New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. Expert Opin Pharmacother. (2021) 22:1291–1303. 10.1080/14656566.2021.1892641
    1. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. . Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: results from the national epidemiologic survey on alcohol and related conditions. JAMA Psychiatry. (2017) 74:911–23. 10.1001/jamapsychiatry.2017.2161
    1. White A, Castle IJ, Chen CM, Shirley M, Roach D, Hingson R. Converging patterns of alcohol use and related outcomes among females and males in the United States, 2002 to 2012. Alcohol Clin Exp Res. (2015) 39:1712–26. 10.1111/acer.12815
    1. Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes ZW, et al. . Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res. (2001) 25:502–7. 10.1111/j.1530-0277.2001.tb02242.x
    1. Frezza M. Padova Cd, Pozzato G, Terpin M, Baraona E, Lieber CS. High Blood Alcohol Levels in Women — The Role of Decreased Gastric Alcohol Dehydrogenase Activity and First-Pass Metabolism. N Engl J Med. (1990) 322:95–9. 10.1056/NEJM199001113220205
    1. McCaul ME, Roach D, Hasin DS, Weisner C, Chang G, Sinha R. Alcohol and women: a brief overview. Alcohol Clin Exp Res. (2019) 43:774–9. 10.1111/acer.13985
    1. Brick J, Nathan PE, Westrick E, Frankenstein W, Shapiro A. The effect of menstrual cycle on blood alcohol levels and behavior. J Stud Alcohol Drugs. (2015) 47:472–7. 10.15288/jsa.1986.47.472
    1. Cole-Harding S, Wison JR. Ethanol metabolism in men and women. J Stud Alcohol Drugs. (1987) 48:380–7. 10.15288/jsa.1987.48.380
    1. Sutker PB, Goist KC, King AR. Acute alcohol intoxication in women: relationship to dose and menstrual cycle phase. Alcohol Clin Exp Res. (1987) 11:74–9. 10.1111/j.1530-0277.1987.tb01266.x
    1. Warren JG, Fallon VM, Goodwin L, Gage SH, Rose AK. Menstrual Cycle Phase, Hormonal Contraception, and Alcohol Consumption in Premenopausal Females: a Systematic Review. Front Global Women Health. (2021) 2:745263. 10.3389/fgwh.2021.745263
    1. Peltier MR, Verplaetse TL, Mineur YS, Petrakis IL, Cosgrove KP, Picciotto MR, et al. . Sex differences in stress-related alcohol use. Neurobiol Stress. (2019) 10:100149. 10.1016/j.ynstr.2019.100149
    1. Becker JB, Koob GF. Sex differences in animal models: focus on addiction. Pharmacol Rev. (2016) 68:242–63. 10.1124/pr.115.011163
    1. Sharrett-Field L, Butler TR, Reynolds AR, Berry JN, Prendergast MA. Sex differences in neuroadaptation to alcohol and withdrawal neurotoxicity. Pflugers Arch. (2013) 465:643–54. 10.1007/s00424-013-1266-4
    1. Haber PS, Riordan BC, Winter DT, Barrett L, Saunders J, Hides L, et al. . New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. Victoria Med J Aust. (2021) 7:S3–32. 10.5694/mja2.51254
    1. Holzhauer CG, Cucciare M, Epstein EE. Sex and gender effects in recovery from alcohol use disorder. Alcohol Res. (2020) 40:03. 10.35946/arcr.v40.3.03
    1. Morley KC, Teesson M, Sannibale C, Baillie A, Haber PS. Clinical predictors of outcome from a randomised controlled trial for alcohol dependence. Alcohol Alcohol. (2010) 45:520–6. 10.1093/alcalc/agq068
    1. Schick MR, Spillane NS, Hostetler KL. A call to action: a systematic review examining the failure to include females and members of minoritized racial/ethnic groups in clinical trials of pharmacological treatments for alcohol use disorder. Alcohol Clin Exp Res. (2020) 44:1933–51. 10.1111/acer.14440
    1. Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and alcoholism. (2014) 49:654–60. 10.1093/alcalc/agu062
    1. Muller CA, Geisel O, Pelz P, Higl V, Kruger J, Stickel A, et al. . High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. (2015) 25:1167–77. 10.1016/j.euroneuro.2015.04.002
    1. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. . Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. (2007) 370:1915–22. 10.1016/S0140-6736(07)61814-5
    1. Garbutt JC, Kampov-Polevoy AB, Pedersen C, Stansbury M, Jordan R, Willing L, et al. . Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacology. (2021) 46:2250–6. 10.1038/s41386-021-01055-w
    1. Pierce M, Sutterland A, Beraha E, Morley K, Van den Brink W. Efficacy, tolerability and safety of low dose and high dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacology. (2018) 28:795–806. 10.1016/j.euroneuro.2018.03.017
    1. Rose AK, Jones A. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction. (2018) 113:1396–406. 10.1111/add.14191
    1. Morley KC, Baillie A, Fraser I, Furneaux-Bate A, Dore G, Roberts M, et al. . Baclofen in the treatment of alcohol dependence with or without liver disease (BacALD): a multi-site, randomised, double-blind, placebo-controlled trial. Br J Psychiatry. (2018) 212:362–9. 10.1192/bjp.2018.13
    1. Logge WB, Morris RW, Baillie AJ, Haber PS, Morley KC. Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berl). (2021) 238:1291–302. 10.1007/s00213-019-05192-5
    1. Logge WB, Baillie AJ, Haber PS, Morley KC. Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. Hum Psychopharmacol. (2020) 35:e2722. 10.1002/hup.2722
    1. Morley KC, Logge WB, Fraser I, Morris RW, Baillie AJ, Haber PS. High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study. Eur Neuropsychopharmacol. (2021) 46:28–36. 10.1016/j.euroneuro.2021.02.010
    1. Agabio R, Sinclair JM, Addolorato G, Aubin HJ, Beraha E, Fabio Caputo F, et al. . The use of baclofen to treat patients with alcohol use disorder: the cagliari expert consensus statement. Lancet Psychiatry. (2018) 5:957–60. 10.1016/S2215-0366(18)30303-1
    1. Morley KC. Commentary on Donoghue: low prescribing rates of pharmacotherapy for alcohol use disorder limit potential public health impact. Addiction. (2021). 10.1111/add.15532
    1. Rombouts SA, Baillie A, Haber PS, Morley KC. Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol Alcohol. (2019) 54:272–8. 10.1093/alcalc/agz026
    1. Morley KC, Leung S, Baillie A, Haber PS. The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemp Clin Trials. (2013) 36:348–55. 10.1016/j.cct.2013.08.002
    1. Sobell LC, Maisto SA, Sobell MB, Cooper A. Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther. (1979) 17:157–60. 10.1016/0005-7967(79)90025-1
    1. Flannery B, Volpicelli J, Pettinati H. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. (1999) 23:1289–95. 10.1111/j.1530-0277.1999.tb04349.x
    1. Campbell UC, Morgan AD, Carroll ME. Sex differences in the effects of baclofen on the acquisition of intravenous cocaine self-administration in rats. Drug Alcohol Depend. (2002) 66:61–9. 10.1016/S0376-8716(01)00185-5
    1. Liu X, Herbison AE. Estrous cycle- and sex-dependent changes in pre- and postsynaptic GABAB control of GnRH neuron excitability. Endocrinology. (2011) 152:4856–64. 10.1210/en.2011-1369
    1. Kirson D, Khom S, Rodriguez L, Wolfe SA, Varodayan FP, Gandhi PJ, et al. . Sex Differences in Acute Alcohol Sensitivity of Naive and Alcohol Dependent Central Amygdala GABA Synapses. Alcohol Alcohol. (2021) 56:581–8. 10.1093/alcalc/agab034

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する